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Abstract
Copper metabolism MURR1 domain 1 (COMMD1) protein is a multifunctional protein, and
its expression has been correlated with patients’ survival in different types of cancer. In
vitro studies revealed that COMMD1 plays a role in sensitizing cancer cell lines to cisplatin,
however, the mechanism and its role in platinum sensitivity in cancer has yet to be estab-
lished. We evaluated the role of COMMD1 in cisplatin sensitivity in A2780 ovarian cancer
cells and the relation between COMMD1 expression and response to platinum-based ther-
apy in advanced stage high-grade serous ovarian cancer (HGSOC) patients. We found that
elevation of nuclear COMMD1 expression sensitized A2780 ovarian cancer cells to cis-
platin-mediated cytotoxicity. This was accompanied by a more effective G2/M checkpoint,
and decreased protein expression of the DNA repair gene BRCA1, and the apoptosis inhib-
itor BCL2. Furthermore, COMMD1 expression was immunohistochemically analyzed in
two tissue micro-arrays (TMAs), representing a historical cohort and a randomized clinical
trial-based cohort of advanced stage HGSOC tumor specimens. Expression of COMMD1
was observed in all ovarian cancer samples, however, specifically nuclear expression of
COMMD1 was only observed in a subset of ovarian cancers. In our historical cohort,
nuclear COMMD1 expression was associated with an improved response to chemotherapy
(OR = 0.167; P = 0.038), although this association could not be confirmed in the second
cohort, likely due to sample size. Taken together, these results suggest that nuclear
expression of COMMD1 sensitize ovarian cancer to cisplatin, possibly by modulating the
G2/M checkpoint and through controlling expression of genes involved in DNA repair and
apoptosis.
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Introduction
CoppermetabolismMURR1 domain 1 (COMMD1) protein is a small ubiquitously expressed
protein, which has been shown to effect tumor cell behavior and survival [1–4]. According to
the Oncomine database, COMMD1 is differentially expressed in multiple cancer types [5], and
decreasedCOMMD1 expression in endometrial cancer tissue was shown to correlate with a
worse overall survival [1]. One of the proposedmechanisms of COMMD1 in mediating the
behavior of cancer involves its inhibitory action on the activity of the transcription factors hyp-
oxia inducible factor 1 (HIF-1) and nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) [1,4]. HIF-1 and NF-κB both have a significant role in tumor behavior and clini-
cal outcome, including ovarian cancer [6–8].
Expression of COMMD1 is predominantly observed in the cytoplasm of most cell types,
although an important role for COMMD1 in the nucleus has been revealed [9–11]. In complex
with an E3 ubiquitin ligase, nuclear COMMD1 promotes the proteasomal degradation of the
NF-κB subunit p65, which leads to inhibition of transcriptional activity of NF-κB [12–18].
COMMD1 also represses HIF-1 activity [19,20], and elevated nuclear COMMD1 expression
augments its inhibitory effect on both NF-Ф06BB and HIF-mediated transcription [10]. Addi-
tionally, nuclear COMMD1was suggested to participate in the cellular response to DNA dam-
age, through its ability to interact with the DNA repair proteins Breast Cancer 1 Early Onset
(BRCA1), BRCA1-associated RING domain protein 1 (BARD1) and Checkpoint kinase 2
(Chk2) [3]. Furthermore, ablation of COMMD1 resulted in increased sensitivity to DNA-dam-
aging agents, including cisplatin, in several cell lines [3,21]. The exact mechanism underlying
this effect, and whether COMMD1 expression levels are associated with the response to plati-
num-based therapy in cancer patients remains unclear.
In this study, we investigated the role of COMMD1 in cisplatin sensitivity, and assessed
COMMD1 expression in two cohorts of patients treated for advanced stage ovarian cancer. We
show that increased levels of nuclear COMMD1 affect cisplatin sensitivity in ovarian cancer
cells in vitro, and that nuclear COMMD1 expression in ovarian cancer tumor tissue is associ-
ated with improved response to cisplatin treatment in one out of two analyzed patient cohorts.
Materials and Methods
Cell lines
Human embryonic kidneyHEK293T cells (ATCC, #CRL-3216), HeLa cervical cancer cells
(ATCC, #CCL-2) andMBA-MB-231 breast cancer cells (ATCC, #HTB-26) were cultured in Dul-
becco’s modifiedEaglemediumGlutaMAX™, supplemented with 10% fetal calf serum (FCS) and
1% penicillin-streptomycin (pen/strep). The human ovarian cancer cell lines A2780 and the cis-
platin-resistant derivative A2780/CP70 were a kind gift of Prof. Steven de Jong and were described
previously [22]. A2780, A2780/Cp70 and Peo14 (Sigma, 10032311) ovarian cancer cells were cul-
tured in RPMImediumGlutaMAX™, supplemented with 10% FCS and 1% pen/strep. All cell lines
were cultured at 5% CO2 and 21%O2. The HeLa, HEK293T, A2780 andMDA-MB-231 cell lines
in which COMMD1was stably depleted using shRNA were maintained inmedia supplemented
with puromycin (1 μg/ml) as previously described [1,19,20]. A2780 and Peo14 cell lines stably
expressing COMMD1-Flagwere generated using the retroviral expression vector pBabe-Puro. To
produce retrovirus particles,HEK293T cells were transfectedwith pBabe-Puro or pBabe-Puro-
COMMD1-Flag in combination with packaging plasmids pMDLG-pRRE, pH-CMV-G and
pRSV-Rev. Virus-containing supernatant culture mediumwas filtered (0.45micron, Corning),
mixed with polybrene (4 μg/ml) and used for infection for three consecutive 12-hour periods.
Twenty-four hours after the third infection, puromycin was added (1 μg/ml) for selection.
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Western blotting
For Western blotting, total cell lysates were obtained using NP40 buffer (0.1% Nonidet P-40
(NP-40), 0.4 M NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA) supplemented with protease
and phosphatase inhibitors (Roche). For the isolation of cytosolic fractions, cells were lyzed in
buffer A (10 mMHepes (pH 7.9), 10 mMKCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.15%NP-40, 1
mMDTT) with protease and phosphatase inhibitors (Roche). Lysates were centrifuged at
12,000 g for 30 seconds at 4°C, and supernatants were taken as cytosolic fraction. The pellets
were washed with ice-cold phosphate-buffered saline (PBS) and lyzed in buffer B (20 mM
Hepes (pH 7.9), 400 mMNaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 1 mMDTT). After
sonication (5 seconds at 50 watt), samples were centrifuged at 12,000 g for 15 minutes at 4°C,
and supernatants were taken as nuclear fractions. Protein concentration was determined using
Bradford assay (Biorad). Thirty micrograms of protein was separated using SDS-PAGE and
transferred to Amersham Hybond-P PVDF Transfer Membrane (GE Healthcare; RPN303F).
Membranes were blocked in 5% milk in Tris-buffered saline-0.01%Tween20 and incubated
with the indicated antibodies.Membranes were visualized using a ChemiDocXRS+ System
(Bio-Rad) using Image Lab software version 5.2.1 (Bio-rad). Images have been cropped for pre-
sentation, but full-size images are presented in S4 Fig.
Immunofluorescence
A2780-empty vector (EV) and A2780-COMMD1 cells were cultured on coverslips for 24
hours, fixed in ice-cold fixative (4% paraformaldehyde and 0.5% glutaraldehyde in PBS) and
incubated for 18 minutes at room temperature in the dark, followed by permeabilizationwith
0.2% Triton X-100 in PBS for 4 minutes. Subsequently, cells were incubated with 10 μg/ml pri-
mary antibody directed against COMMD1 (R&D biosystems; MAB7526) in IF buffer (Tris-
buffered saline plus human serum cocktail, Sigma; H4522) overnight at 4°C in a humidifier
chamber. After three washes in PBS, cells were incubated with Fluorescein (FITC)-conjugated
anti-rabbit antibody (1:300; Jackson Immunoresearch Laboratories; 711095152) for 1 hour at
room temperature or overnight at 4°C in a humidifier chamber. After three washes in PBS, cov-
erslips were mounted on slides with Vectashield mounting mediumwith DAPI (Vector Labo-
ratories; H-1200). Images were obtained with a Zeiss Axio Imager2 with a Plan-
APOCHROMAT 63x/1.4 Oil objective, using ZEN software (Zeiss).
Antibodies
We used the following antibodies:mouse monoclonal anti-COMMD1 (clone 3B3; Abcam;
ab131597), rabbit polyclonal anti-COMMD1 (Proteintech Group; 11938-1-AP), mouse mono-
clonal anti-β-Actin (Sigma-Aldrich;A5441), rabbit polyclonal anti-Tubulin (Abcam; ab4047),
rabbit polyclonal anti-Lamin A/C (Cell Signaling Technology; #2032), mouse monoclonal anti-
Bcl2 (Santa Cruz Biotechnology; sc-509), rabbit monoclonal anti-PARP (Cell Signaling Tech-
nology; #9532), rabbit polyclonal anti-cleaved-caspase3 (Cell Signaling Technology; #9661),
mouse monoclonal anti-phospho-Ser10-Histone H3 antibody, (Cell Signaling Technology;
#9706), mouse monoclonal anti-XIAP (BD Biosciences, # 610716), rabbit polyclonal anti-
BRCA1 (Cell Signaling Technology; #9010), mouse monoclonal anti-Hsp90 (AC88) (Enzo;
ADI-SPA-830), rabbit monoclonal anti-phospho-Ser139-H2AX (Cell Signaling Technology;
#9718), Alexa-488-conjugated polyclonal anti-mouse (Molecular Probes; A-11001), Alexa-
647-conjugated polyclonal anti-rabbit (Molecular Probes, A-21244), HRP-conjugated poly-
clonal goat anti-rabbit IgG (H + L) (Bio-Rad; #170–6515), HRP-conjugated polyclonal goat
anti-mouse IgG (H + L) (Bio-Rad; #170–6516).
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Viability assay
To measure cell viability 2,000 cells were plated in 96-well plates (triplicates for each condi-
tion). 24 hours after plating, cells were treated either with control medium or medium contain-
ing cisplatin (Tocris) at indicated concentrations for 72 hours. After incubation, 20 μl of 5 mg/
ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) was added for 3
hours. Subsequently, culture mediumwas removed, and cells were incubated in dimethyl
sulphoxide (DMSO) for 30 minutes. Absorbance was measured at 520 nm using a Biorad
microplate reader. Viability was measured by calculating relative MTT conversion. MTT con-
version of cells treated with control mediumwas used as a reference.
Flow cytometry
A2780-EV and A2780-COMMD1 cells were harvested after 24 hours of incubation with 2 μM
cisplatin and fixed in ice-cold 70% ethanol. Cells were stained with mouse anti-phospho-
Ser10-Histone H3 antibody and with rabbit anti-phospho-Ser139-H2AX and subsequently
stained with Alexa-488-conjugated anti-mouse and Alexa-647-conjugated anti-rabbit anti-
body. In addition, counterstaining was performedwith propidium iodide/RNAse (Sigma-
Aldrich). Cell cycle distribution, phospho-Histone H3 and anti-phospho-H2AX positivity
were analyzed on a FACSCalibur (BectonDickinson Biosciences) equipped with CellQuest
software. Per sample, at least 10,000 events were analyzed, and indicated results show averages
and standard deviations of three independent experiments.
Gene expression analysis
A2780-EV and A2780-COMMD1 cells were grown to 70% confluency and were left untreated
or were treated with 2mM cisplatin for 24hrs. Cells were harvested in QIAzol Lysis Reagent
(Qiagen), and total RNA was isolated by chloroform extraction. Isopropanol-precipitated and
ethanol-washed RNA pellets were dissolved in RNase/DNase free water. One microgram of
RNA was used to prepare cDNA with the Transcriptor Universal cDNA Master (Roche),
according to the protocol provided by the manufacturer. 20 ng cDNA was used for subsequent
quantitative real-time PCR (qRT-PCR) analysis using FastStart SYBR GreenMaster (Roche)
and 7900HT Fast Real-Time PCR System (Applied Biosystems). The following PCR program
was used: 50°C/2 minutes, 95°C/10 minutes, 40 cycles of 95°C/15 seconds and 60°C/1 minute.
Expression data were analyzed using SDS 2.3 software (Applied Biosystems), using the ‘stan-
dard curve’ method of calculation. GAPDH expression was used as an internal control. Primer
sequences are listed in S1 Table.
Patients
Two previously describedovarian cancer tissue microarrays (TMA1 and TMA2) were analyzed
in this study [23,24]. TMA1 includes retrospectively collected data and was used as an explor-
atory TMA, whereas TMA2 includes prospectively collected data and was used to validate our
observations from TMA1.
ConcerningTMA1: betweenApril 1988 andMay 2006, 354 patients were treated in the Uni-
versity Medical Center Groningen (UMCG) for ovarian cancer. Tumor tissues of 232 patients
were included on TMA1 as describedpreviously [25]. For this study, follow-up data of these
patients were updated and new patients (treated between 2002 and 2006) were additionally
included. 126 of these patients were diagnosedwith advanced stage HGSOC, and chemo-naïve
tumor tissue of these patients was used for exploratory immunohistochemical analysis. After
primary surgery, patients received platinum-based chemotherapy (cisplatin or carboplatin,
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with or without a taxane). Tissue collection and storage of clinicopathological and follow up
data was only performed upon patients’ approval via informed consent. Clinical data was col-
lected in the UMCG and stored digitally in a central database, which is solely accessible by two
dedicated data managers. Statistical analysis was performedwith an anonymized dataset
extracted from the central database. Protection of patient identity was thereby warranted and
according to Dutch law no further Institutional ReviewBoard approval was necessary. Patient
staging was done according to the FIGO (International Federation of Gynaecology and Obstet-
rics) criteria. Tumor grading and classification was determined by a gynecologicalpathologist.
When sufficient tumor tissue and complete follow up information was available, patient data
were considered suitable for inclusion for analysis. We selected advanced stage (stage 3 and 4)
HGSOC patients (n = 126). To retrospectively evaluate response to chemotherapy, we defined
two groups of patients demonstrating extreme therapy responses; a ‘responder’ and a ‘non-
responder group’ as previous described [25]. Patients with advanced stage HGSOC,2 cm
residual disease after debulking surgery, adjuvant platinum-based chemotherapy and a pro-
gression free survival (PFS) of>18 months were considered ‘responders’. When PFS was<6
months, patients were considered ‘non-responders’.
TMA2 comprises tumor tissues of patients who were treated as part of a Dutch multicenter
randomized phase II study [26]. The clinical trial of which patient material was included on
TMA2 was registered as NTR1491 in the publically accessible Dutch Trial Registry (trialregis-
ter.nl), part of the Dutch CochraneCentre. Details and results of this study were published in
[26]. Data were prospectively collected. In this study, patients were treated with carboplatin/
docetaxel and randomized to celecoxib (twice daily 400 mg) or a placebo treatment. In short,
patients with histopathological conformation of epithelial ovarian cancer, fallopian tube or pri-
mary peritoneal carcinomas, FIGO IC-IV, were included. The primary study objectives were
response rate and PFS. Response rate was determined using CA125 levels and the Response
Evaluation Criteria in Solid Tumors (RECIST version 1.0). BetweenMarch 2003 and Novem-
ber 2008, a total of 202 patients enrolled the study, of which 196 were eventually included for
statistical analysis. Written informed consent was provided before patients were included. No
differences in patient outcome between the two study arms were observed. Sufficient tumor
specimens of 121 out of 196 patients were available for immunohistochemical analysis. Of
these patients, 67 were diagnosedwith advanced stage HGSOC. To test our hypothesis from
TMA1, a ‘responder’ and a ‘non-responder’ group was defined in a similar way as for TMA2.
However, instead of 2 cm residual disease after debulking surgery, the presence of residual dis-
ease was used as a metric for response to treatment.
For the patients obtained from the UMCG in The Netherlands, patients gave informed con-
sent for collection and storage of tissue samples in a tissue bank for future research. All relevant
patient data were retrieved and transferred into an anonymous, password-protected, database.
The patients' identity was protected by study-specific, unique patient codes and their true iden-
tity was only known to two dedicated data managers. According to Dutch regulations, these
precautions meant no further institutional review board approval was needed (http://www.
federa.org/). TMA1 is not prospectively collected, TMA2 is prospectively collected, but not for
the purpose of this study. From the co-authors, Anna K.L. Reyners and Ate G.J. van der Zee
are treating physicians, although they did not treat all patients themselves.
Immunohistochemistry
TMA1 and TMA2 were constructed as previously described [23,24,26]. For immunohis-
tochemistry, 4 μm sections were de-paraffinized in xylene. Subsequently, antigen retrieval was
performed by 15 minutes boiling in TRIS/EDTA (pH 9.0) buffer. Endogenous peroxidase was
COMMD1 and Cisplatin Sensitivity in Ovarian Cancer
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blocked by 0.3% hydrogen peroxide for 30 minutes. COMMD1was stained using mouse
monoclonal anti-COMMD1 (1:50; clone 3B3; Abcam, ab131597). Detectionwas conducted
using a horseradish peroxidase (HRP) conjugated secondary rabbit anti-mouse antibody
(1:100; DAKO; P0260) and a HRP-conjugated tertiary goat anti-rabbit antibody (1:100;
DAKO; P0448). Staining was visualizedwith 3’3-diaminobenzidine tetrahydrochloride and
counterstained with hematoxylin. HEK293T and HeLa cell lines, in which COMMD1 expres-
sion was stably depleted using shRNA-mediated COMMD1 knockdown, were used as negative
controls for immunohistochemistry [1]. Cells were embedded in paraffin, sliced in 4 μm sec-
tions and subsequently mounted on amino-propyl-ethoxy-silan-coated glass slides. Slides were
incubated with mouse monoclonal anti-COMMD1 (1:100; clone 3B3; Abcam; ab131597) fol-
lowing the similar protocol as described above. Twenty-one randomly selected tumor samples
from ovarian cancer patients were used to stain whole section for exploratory analysis of
COMMD1 immunohistochemistry (Fig 1C). Statistical analysis of this group of staining was
not performed due to small samples size, and because these tumors are also part of TMA1.
Quantification workflow of immunohistochemical COMMD1 staining.
For semi-quantitative analysis, immunohistochemical slides were scanned on a Hamamatsu
NanoZoomer, and saved as TIFF files. Image analysis was subsequently performed using the
ImageJ-based software package FIJI [27]. 3,3'-Diaminobenzidine (DAB) staining and hematox-
ylin staining were deconvoluted using ‘colour deconvolution’ with ‘H DAB’ settings. Images
were subsequently converted into 8-bit gray scale images and inverted. Values of DAB staining
were left unaltered, whereas hematoxylin staining was contrast enhanced to define cytoplasm/
nucleus boundaries. Vectors with a length of ~100 pixels were subsequently used to measure
DAB staining intensities across cells.
Evaluation of staining
Cytoplasmic and nuclear COMMD1 expression levels were semi-quantitative scored by two
independent observers (AF and HWW) as previously described [28]. Patients were included
for statistical analysis if 2 cores (out of 4) were evaluable for COMMD1 expression. Observ-
ers had a concordance in scores in> 90% of the cases. Discordances in scoring were reviewed
by AF and HWW to reach consensus for a definitive score. The total immunoreactive score
(IRS, 0–8) was constituted by adding the score of staining intensity (0–3) with the percentage
of tumor stained (0–5). Staining intensity was scored as negative (0), weak positive (1), positive
(2), strong positive (3). Subsequently, percentage of tumor cells stained was scored as 0% (0),
0–5% (1), 5–25% (2), 25–50% (3), 50–75% (4),>75% (5). Scores for cytoplasmic COMMD1
were arbitrary divided into ‘low’ (IRS = 0–6) and ‘high’ (IRS7), while scores for nuclear
COMMD1were divided in negative (IRS = 0) and positive (IRS 1).
Statistical analysis
Statistical analyses were performed using SPSS 22.0 for Windows (IBM) and were previously
described [23–25]. In short, in TMA1 logistic regression was used to evaluate associations
between cytoplasmic/nuclear COMMD1 expression and patient characteristics. Survival analy-
ses for disease-specificsurvival (DSS) and PFS were performedusing the Cox proportional haz-
ards model. None of the variables violated the proportional hazards assumption. In TMA1
DSS was defined as time from primary (debulking) surgery to death caused by ovarian cancer
or last follow up alive. PFS was defined as time from primary surgery to progression/relapse of
the disease, death, or last follow up. Median follow-up for the 126 HGSOC patients was 21
months. Only P-values0.10 in the univariate analysis were included for multivariate analysis
if applicable. For TMA2, we performed similar analysis as for TMA1.
COMMD1 and Cisplatin Sensitivity in Ovarian Cancer
PLOS ONE | DOI:10.1371/journal.pone.0165385 October 27, 2016 6 / 21
Fig 1. Antibody validation and exploratory immunostaining for COMMD1 in human ovarian tumor samples. (A)
Representative immunohistochemical COMMD1 staining in paraffin embedded HEK293T and HeLa cells depleted for
COMMD1. (B) HEK293T and HeLa cells were stably silenced for COMMD1 as shown by immunoblotting. (C)
Observational immunostainings for COMMD1, including its control IgG1 immunostaining in a consecutive slide, in
COMMD1 and Cisplatin Sensitivity in Ovarian Cancer
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In vitro data shown were derived from three independent experiments ± standard error of
the means (SEM). Analyses were performed using GraphPad version 6.05 (GraphPad soft-
ware). Student’s t-test was used to test the significance. For all experiments a P-value of<0.05
was considered as statistically significant.
Results
COMMD1 expression in human ovarian tumor samples
To assess the expression of COMMD1 in ovarian tumors, we first determined the specificity of
the anti-COMMD1 antibody in HeLa and HEK293T cell lines, which were stable depleted for
COMMD1 (Fig 1A and 1B) [1,19]. In contrast to the control cells, almost no staining of COM
MD1 was detected in COMMD1-depleted cells (Fig 1A). These results certified the specificity of
our immunohistochemical staining of COMMD1. Next, we stained COMMD1 in a panel of
whole sections of ovarian cancer tissues (n = 21, Fig 1C), and observedCOMMD1 expression in
all samples. Interestingly, however, we detected a marked nuclear expression of COMMD1 in a
subset of cancer tissue samples, in addition to cytoplasmic staining of COMMD1 (Fig 1C). Using
semi-quantitative analysis of COMMD1 immunohistochemical stainings (Fig 1D), we indeed
found consistently lower levels of nuclear COMMD1 in ‘nuclear COMMD1-negative’ tumor
samples when compared to ‘nuclear COMMD1-positive’ tumor samples (Fig 1E).
Increased nuclear expression of COMMD1 sensitizes ovarian cancer
cells to cisplatin treatment
The differential subcellular expression of COMMD1 in ovarian cancer, together with the notion
that nuclear COMMD1 inhibits NF-κB and HIF activity and that COMMD1might have a func-
tion in DNA damage response prompted us to evaluate whether nuclear COMMD1 affects the
sensitivity of ovarian cancer cells to cisplatin [3,10]. To this end, we stably overexpressed FLAG-
taggedCOMMD1 in A2780 ovarian cancer cells.We previously showed that the FLAG tag does
not interfere with COMMD1 function, as FLAG-taggedCOMMD1 can rescue the lethal pheno-
type of Commd1-/- mice [29]. Stable overexpression of COMMD1-FLAG in A2780 cells resulted
in a 2.6-fold increase in cytosolic expression (Fig 2A) and 5.9-fold increase in nuclear COMMD1
levels compared to control-transfected cells (A2780-EV), in which COMMD1 is predominantly
cytoplasmic (Fig 2A). Indirect immunofluorescence staining validated this increase in nuclear
COMMD1 levels (Fig 2B). In the control cells we observedcytoplasmic vesicular localization of
COMMD1 and a very weak nuclear staining, similar as previously reported for other cell lines
[9–11,29]. However, in addition to a vesicular COMMD1 localization, A2780-COMMD1 cells
also showed a significant increase in nuclear COMMD1 expression (Fig 2B). Since the expression
of COMMD1was predominantly increased in the nucleus of A2780-COMMD1 cells, we rea-
soned that these cells reflect the tumors with elevated nuclear COMMD1 expression (Fig 1C)
and therefore represent an elegant model to study the role of aberrant COMMD1 expression on
cisplatin sensitivity. Control A2780 cells (EV), and cells with high nuclear COMMD1 levels were
HGSOC patient samples demonstrating either absent or presence of nuclear COMMD1. (D) Quantification workflow of
immunohistochemical COMMD1 staining. Image analysis was performed using the ImageJ-based software package
FIJI. DAB staining and hematoxylin staining were deconvoluted and images were subsequently converted into 8-bit gray
scale images. Hematoxylin staining was used to define cytoplasm/nucleus boundaries. Vectors were subsequently
used to measure DAB staining intensities across cells and quantify nuclear COMMD1 levels in relation to cytoplasmic
levels. (B) Three ‘nuclear COMMD1-negative’ (n = 10 cells per tumor sample) and three ‘nuclear COMMD1-positive’
tumor samples were analyzed. Averages and standard deviations are indicated. Relative nuclear COMMD1 levels to
cytoplasmic levels are plotted per tumor sample.
doi:10.1371/journal.pone.0165385.g001
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Fig 2. Increased nuclear COMMD1 expression in A2780 cells enhanced cisplatin sensitivity. (A) Subcellular localization
of COMMD1 in A2780 EV and A2780-COMMD1 cells determined by immunoblotting. Intensity of individual bands for COMMD1
was quantified using ImageLab software. After correction for tubulin or lamin A/C expression the relative COMMD1 expression in
A2780-COMMD1 cells was determined. (B) A2780 EV and A2780 COMMD1 cells were stained for COMMD1 (green), and DNA
COMMD1 and Cisplatin Sensitivity in Ovarian Cancer
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treated with different concentrations of cisplatin for 72 hours after which the viability of cells was
measured by MTT conversion. Stable nuclear COMMD1 expression resulted in decreased cell
viability after treatment with 0.5–10 μM cisplatin (Fig 2C). Although to a lesser extend, similar
results were seen in the ovarian cancer cell line Peo14 in which we stably increasedCOMMD1
expression (Fig 2D). This mild effect is likely due to the relative lower overall and nuclear increase
in COMMD1 levels (Fig 2E) compared to A2780-COMMD1 cells (Fig 2A). Next, we determined
the COMMD1 levels in A2780/Cp70 cells, an ovarian cancer cell line, which is 13-fold more
resistant to cisplatin than A2780 cells [30]. A2780/Cp70 cells have reduced cytosolic and nuclear
COMMD1 levels compared to A2780 cells (S1 Fig). To assess the effect of COMMD1 reduction
in cisplatin sensitivity we decreased the COMMD1 levels by shRNA, which diminished cisplatin
sensitivity of A2780 cells (Fig 2F). Taken together, these results show that nuclear levels of
COMMD1 are associatedwith cisplatin sensitivity in ovarian cancer cells.
Elevated nuclear COMMD1 expression ameliorates G2/M cell cycle
checkpoint function upon cisplatin treatment
The fact that COMMD1 can interact with nuclear BRCT domain-containing proteins, led us to
hypothesize that COMMD1may play a role in the DNA damage response. Therefore, we assessed
the effect of increased nuclear expression of COMMD1 on the level of DNA damage and cell cycle
checkpoint behavior in response to cisplatin. The level of DNA breaks upon cisplatin treatment, as
judged by gamma-H2AX foci formation, was not significantly different between the two cell lines
(Fig 3A and 3B). Next, the contribution of nuclear COMMD1 on cell cycle checkpoint function
was determined. First, proliferation rates of the control (EV) and A2780-COMMD1 cells were
studied. As shown in Fig 3C, the proliferation rate was not affected by increased expression of
nuclear COMMD1.However, as expected, cisplatin treatment (2 μM, 24 hours) resulted in accu-
mulation of cells in S phase, which was more pronounced in A2780-COMMD1 cells compared to
control cells (Fig 3C and 3D). Second, the percentage of cells that enteredmitosis, as judged by the
phosphorylation level of Histone-H3, was determined.After 24 hours of cisplatin treatment, a
marked cell cycle arrest at G2 phase was observed in both cell lines (Fig 3E and 3F), but the per-
centage of mitotic cells was further decreasedby elevated nuclear COMMD1 expression (Fig 3E
and 3F). These results indicate that increasedCOMMD1 expression, along with elevated nuclear
COMMD1, ameliorates G2/M checkpoint function in response to cisplatin treatment.
Cisplatin-induced apoptosis is increased in ovarian cancer cells with
elevated levels of nuclear COMMD1
Since apoptosis is the major process contributing to cell death induced by DNA damaging
agents [31], we evaluated whether cells with higher nuclear COMMD1 expression levels more
(blue) and imaged by fluorescent microscopy. The scale bar represents 20 μm. (C) A2780 EV and A2780 COMMD1 cells were
plated in 96-well plates and treated with indicated concentrations of cisplatin. After 72 hours of treatment, cells were incubated
with MTT for 3 hours and the viability of cells was determined by colorimetric measurement. Data are shown from three
independent experiments. Statistical significance was calculated using the Student’s t-test. *: P< 0.05, **: P <0.01, ***: P
<0.001. (D) Overexpression of COMMD1 in Peo14 cells augments cisplatin sensitivity. Control cells (Peo14 EV) and Peo14 cells
stably overexpressing COMMD1-Flag (Peo14 COMMD1) were plated in 96-well plates and treated with indicated concentrations
of cisplatin. After 72 hours of treatment, cells were incubated with MTT for 3 hours and the viability of cells was determined by
colorimetric measurement. Data are shown from three independent experiments. Statistical significance was calculated using the
Student’s t-test. *: P< 0.05. (E) Subcellular localization of COMMD1 in Peo14-EV and Peo14-COMMD1 cells determined by
immunoblotting. Intensity of individual bands for COMMD1 was quantified using ImageLab software. (F) Silencing of COMMD1
results in decreased sensitivity of A2780 cells to cisplatin. Control cells (EV) and COMMD1 silenced A2780 cells (KD) were plated
in 96-well plates and treated with indicated concentrations of cisplatin. After 72 hours of treatment, cells were incubated with MTT
for 3 hours and the viability of cells was determined by colorimetric measurement. Data are shown from three independent
experiments. Statistical significance was calculated using the Student’s t-test. *: P< 0.05
doi:10.1371/journal.pone.0165385.g002
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Fig 3. Elevated nuclear COMMD1 levels increase G2/M checkpoint after cisplatin treatment in A2780 cells.
(A) A2780 cells treated with 2 μM cisplatin for 24 hours were harvested, fixed in 70% ethanol, stained with anti-γ-
H2AX/Alexa-647 and analyzed by flow cytometry. Representative plots of at least 10,000 events are shown. (B)
Percentages indicate average amounts (with SEM) of γ-H2AX-positive cells from three independent experiments.
(C) A2780 cells treated with 2 μM cisplatin for 24 hours were harvested, fixed in 70% ethanol, stained with
propidium iodide and cell cycle distribution was analyzed by fluorescence-activated cell sorting (FACS).
Representative FACS profiles are shown. S-phase cell fraction is marked in pink. (D) Average percentages and
SEM of S-phase cells from three independent experiments are presented. (E) A2780 cells treated with 2 μM
cisplatin for 24 hours were harvested, fixed in 70% ethanol and stained with anti-p-H3/Alexa-488 and analyzed by
flow cytometry. Representative plots of at least 10,000 events are shown. (F) Percentages indicate average
amounts (with SEM) of p-H3 positive cells from three independent experiments. Significance was calculated using
the Student’s t-test (* represents P<0.05).
doi:10.1371/journal.pone.0165385.g003
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efficiently undergo apoptosis after cisplatin-mediatedDNA damage. The apoptotic markers
cleaved caspase-3 and cleaved PARP-1 were higher in A2780-COMMD1 compared to control
cells after 24h of cisplatin treatment (Fig 4A). Next, we analyzed the expression of the anti-apopto-
tic proteins BCL2 and XIAP. Independent of cisplatin treatment, we found that both protein and
mRNA levels of BCL2were significantly lower (Fig 4A, 4B and 4C). Also, the mRNA levels of
XIAP, a direct inhibitor of caspase-3, were reduced, independently of cisplatin treatment (Fig 4C).
However, the protein levels of XIAP were not significantly decreased (Fig 4A and 4B). Further-
more, upon cisplatin incubation, a significant reduction in mRNA and protein levels of the DNA
repair gene BRCA1was observed in A2780-COMMD1 cells (Fig 4A, 4B and 4C). Altogether,
these results suggest that increasedCOMMD1 levels, including elevated COMMD1 levels, causes
impaired expression of the indicated anti-apoptotic and DNA repair genes, which is accompanied
by increased apoptosis after cisplatin treatment.
Fig 4. Increased nuclear expression of COMMD1 leads to elevated apoptosis and impaired gene expression in cisplatin treated A2780
cells. (A) Whole-cell lysates of untreated and 2 μM cisplatin (24 hours) treated A2780 EV and A2780 COMMD1 cells were analyzed by
immunoblotting using the indicated antibodies. (B) Relative protein levels of Bcl2, XIAP, BRCA1 were quantified (n = 3) (C) mRNA levels of the
indicated genes in non-treated and 2 μM cisplatin (24 hours) treated A2780 COMMD1 cells were determined by qRT-PCR and presented relative to
A2780 EV control cells. GAPDH expression was used as an internal control. Average values are presented with SEM. Significance was calculated
using the Student’s t-test. *: P< 0.05, **: P <0.01, ***: P <0.001. (D) Representative immunostaining for both low and high cytoplasmic COMMD1
staining and negative or positive nuclear COMMD1 staining in HGSOC tumor samples. (E) Proposed model of how chemosensitivity for cisplatin is
regulated by nuclear COMMD1 in A2780 EV and COMMD1 ovarian cancer cells.
doi:10.1371/journal.pone.0165385.g004
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COMMD1 expression in advanced stage HGSOC patients
Given the nuclear expression of COMMD1 in a subgroup of ovarian cancer patients (Fig 1C)
and increased cisplatin sensitivity of ovarian A2780 cancer cells with elevated nuclear COM
MD1 levels (Fig 2C), we explored whether the expression and subcellular localization of
COMMD1 in ovarian tumors correlated with patient outcome. To this end, we assessed the
cytoplasmic and nuclear COMMD1 expression in chemo-naive tumor samples of 126 retro-
spectively selected advanced stage HGSOC patients (tissue microarray #1, TMA1). Of note, the
tumor samples analyzed in Fig 1C are representing TMA1. In 94% of these tumor samples,
COMMD1 expression was detected. Of those tumors with positive COMMD1 expression,
cytoplasmic COMMD1 staining was readily detected (>75% of tumor cells stained positive) in
all patients and only differed in intensity. We observed ‘high’ cytoplasmic expression in 43/120
(35.8%) patients, and nuclear expression of COMMD1 in 64/118 (54.2%) patients. Representa-
tive immunohistochemical stainings of cytoplasmic and nuclear COMMD1 are shown in Fig
5A. Patient characteristics are summarized S2 Table.
During the follow up period, 95/126 (75.4%) patients died because of ovarian cancer. Analy-
sis of the entire patient group showed that high cytoplasmic or nuclear COMMD1 staining was
not correlated with disease-specificsurvival (DSS) and progression-free survival (PFS) in uni-
variate cox regression analysis (S3 Table). Residual disease of2 cm after primary surgery was
related with both DSS (HR = 1.755; P = 0.016) and PFS (HR 1.558; P = 0.045). We found no
association (OR 0.257; P = 0.142) between ‘high’ cytoplasmic COMMD1 staining and chemo-
therapy response (Table 1). However, using subgroup analysis, nuclear COMMD1 expression
was significantly less frequently observed in the non-responders group (OR = 0.167; P = 0.038)
in this exploratory TMA1 (Table 1). Representative immunohistochemical stainings of cyto-
plasmic and nuclear COMMD1 of responders (n = 3) and non-responders (n = 3) (Fig 5B).
This result suggests that nuclear COMMD1 is related with improved response to chemother-
apy in a subgroup of advanced stage HGSOC patients.
To confirm these observed associations for nuclear COMMD1 in the exploratory TMA1, we
analyzed COMMD1 protein expression in a second patient cohort (TMA2, S4 Table). This
patient cohort (n = 67) was prospectively collected as part of a clinical study (NTR1491). In 24
tumors, positive nuclear COMMD1 (35.8%) was seen, whereas in 33 tumors no nuclear
COMMD1 staining was observed (49.3%). Using Cox regression analysis, no prognostic value
of nuclear COMMD1 expression was found (DSS: HR = 1.396, P = 0.360; PFS: HR = 1.016,
P = 0.960) (Table 2). To investigate whether nuclear COMMD1 in this patient cohort was asso-
ciated with tumor response to chemotherapy as suggested from the exploratory TMA1 data,
associations between nuclear COMMD1were again analyzed in a subset of patients with dis-
tinct favorable or poor therapy responses. Of the 13 patients included in this analysis, 10
patients were considered as ‘responders’. Of these ‘responders’, 7 patients showed no nuclear
COMMD1 expression, while 3 patients did. The 3 ‘non-responders’ showed nuclear
COMMD1 expression. Due to the small amounts of patients and the absence of non-respond-
ers without nuclear COMMD1 expression in TMA2, no statistically meaningful analysis could
be performed on this specific patient group.
Discussion
We here found that nuclear COMMD1 is associated with the response to cisplatin in ovarian
cancer cells in vitro, and might be related to response to cisplatin treatment in ovarian cancer
patients. The observation that elevated expression of COMMD1 in the nucleus is related to
responses to cisplatin is fascinating, since COMMD1 is predominantly expressed in the cyto-
plasm of most cell types [9–11]. Interestingly, its nuclear expression can be actively controlled
COMMD1 and Cisplatin Sensitivity in Ovarian Cancer
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Fig 5. Examples of COMMD1 levels and localization in ovarian cancer samples. (A) Representative immunohistochemical
stainings of cytoplasmic and nuclear COMMD1 are indicated. (B) Representative immunohistochemical stainings of cytoplasmic and
nuclear COMMD1 of responders (n = 3) and non-responders (n = 3).
doi:10.1371/journal.pone.0165385.g005
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via a nuclear export signal (NES) in an exportin 1 (CRM1)-dependentmanner [10], indicating
that under certain conditions the levels of nuclear COMMD1 can be tightly regulated.
The relation between subcellular COMMD1 localization and response of ovarian cancer
patients to therapy and survival was not established previously. To our knowledge this is the
first study that suggests a link between nuclear COMMD1 levels and therapy response. In our
exploratory patient cohort (TMA1), we observed in a subgroup of advanced stage HGSOC
patients an association between nuclear COMMD1 expression and response to therapy. Since
the exploratory TMA1 was retrospectively collected,we wished to validate our findings in an
independent patient cohort.We therefore analyzed tumor material of HGSOC patients from
the DoCaCel study (NTR1491). Unfortunately, due to the limited number of available patient
tumor specimens, we were unable to test our hypothesis in a second, study-based TMA.
Mechanistically, our in vitro data indicated that the improved cisplatin sensitivity by nuclear
COMMD1 is possibly linked to reduced protein expression of the genes BRCA1, and BCL2.
Table 1. Response to therapy for TMA1: logistic regression analysis for advanced stage HGSOC patients with2 cm residual disease after pri-
mary surgery, and receiving platinum-based chemotherapy and a PFS of <6 months (n = 14) versus PFS of >18 months (n = 16).
OR 95% CI P-value
Lower Upper
Age (continuous) 0.969 0.915 1.026 0.286
Positive nuclear COMMD1 0.167 0.031 0.904 0.038
High cytoplasmic COMMD1 0.257 0.042 1.573 0.142
OR = odds ratio, CI = confidence interval
doi:10.1371/journal.pone.0165385.t001
Table 2. Disease-specific and progression-free survival analysis in relation to nuclear COMMD1 expression in tumors of patients with advanced
stage HGSOC from TMA2.
Disease-specific survival
HR 95% CI P-value
Lower Upper
Age (continuous) 1.019 0.991 1.048 0.181
Residual disease
None Ref.
Present 1.534 0.777 3.027 0.218
Unknown 3.503 1.122 10.939 0.031
No primary debulking 1.720 0.600 4.931 0.313
Nuclear COMMD1 1.396 0.684 2.850 0.360
Progression-free survival
HR 95% CI P-value
Lower Upper
Age (continuous) 1.015 0.988 1.044 0.280
Residual disease
None Ref.
Present 1.974 1.021 3.816 0.043
Unknown 4.655 1.454 14.903 0.010
No primary debulking 2.378 0.927 6.103 0.072
Nuclear COMMD1 1.016 0.553 1.866 0.960
HR = hazard ratio, CI = confidence interval
doi:10.1371/journal.pone.0165385.t002
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BRCA1 is a key component of the homologous recombination DNA repair pathway, and
reduced expression or mutational inactivation of BRCA1 was reported to increase sensitivity to
cisplatin [32]. In addition to its role in DNA repair, BRCA1 is also implicated in various other
cellular functions, including transcription regulation, a processes which is also involved in the
responsiveness of cells to cisplatin. In this context, BRCA1 was demonstrated to regulate the
expression of the NF-κB anti-apoptotic target genes BCL2 and XIAP, in a fashion dependent
on the NF-κB subunit p50 [33]. Since COMMD1 inhibits NF-κB activity and can interact with
BRCA1, it is tempting to speculate that nuclear COMMD1 represses the BRCA1-p50 mediated
transcription of BCL2 and XIAP and thereby sensitizes ovarian cancer cells to cisplatin-
Fig 6. Model of how COMMD1 may influence responses to cisplatin.
doi:10.1371/journal.pone.0165385.g006
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induced apoptosis (model in Fig 6). This idea is further supported by the observation that
nuclear COMMD1 is important to suppress transcription of NF-κB target genes [10,13–15].
It has beenwell established that COMMD1 also regulates the function of the copper trans-
porters ATP7A and ATP7B [11,21,34–37], and both copper transporters have been implicated
in cisplatin resistance [38–41]. The mechanism of ATP7A/B mediated cisplatin resistance
remains unclear, but it has been postulated that thesemetal transporters might reduce the cyto-
toxic effect of cisplatin. However, we did not observe a significant difference in cisplatin-
inducedDNA damage as judged by gamma-H2AX formation, suggesting that increased
COMMD1 expression does not affect the function of the copper-transporting ATPases in
intracellular accumulation of cisplatin. Gamma-H2AX foci also reflects DNA breaks that are
not repaired through BRCA1, and since gamma-H2AX remains associated with sites of DNA
breaks even after repair, which could explain why decreased BRCA1 levels upon COMMD1
overexpression was not associated with altered gamma-H2AX foci numbers.
Remarkably, our results on the role of COMMD1 in cisplatin sensitivity are in contradiction
with prior data that demonstrated that reduced levels of COMMD1 in a breast cancer cell line
[3] and a hepatoma cell line [21] lead to increased cisplatin sensitivity. We were able to repli-
cate the enhanced cisplatin sensitivity in the breast cancer cell line MDA-MB-231 upon
COMMD1 silencing (S2 Fig), which would indicate that the effects of COMMD1 on cisplatin
response and tumor behavior are cell-type specific. A cell-type specific role of COMMD1 in
tumor behavior is corroborated by prior studies. In diffuse large B-cell lymphoma (DLBCL)
high COMMD1 expression is correlated with poor prognosis [2] and is associated with aggres-
sive forms of (DLBCL) [42]. Increased COMMD1 expression is also common in primarymedi-
astinal B-cell lymphoma (PMBL) cells lines and in PMBL patients [43]. In contrast, in many
other types of cancer (e.g. seminoma, ovarian, breast, and prostate cancer) a reduced expres-
sion of COMMD1 has been found. This decreasedCOMMD1 expression is correlated with
cancer behavior and reduced survival rate [1,4,17,44].
Taken together, our data suggest that elevated levels of nuclear COMMD1 confer A2780
ovarian cancer cells to be more sensitive to platinum-based chemotherapy. In line with our in
vitro data, we found that increased expression of COMMD1 in the nucleus of ovarian tumors
is associated with improved response to cisplatin therapy. Better understanding of the mecha-
nism that regulates nuclear expression of COMMD1 is required and might uncover novel ther-
apeutic targets to improve cellular responses to platinum-based chemotherapeutics.
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S1 Fig. Reduced cytosolic and nuclear COMMD1 levels correlates with increased cisplatin
resistance of A2780 ovarian cancer cells. Subcellular localization of COMMD1 in A2780 and
A2780/Cp70 cells determined by immunoblotting.
(PDF)
S2 Fig. Silencing of COMMD1 results in increased cisplatin sensitivity of breast cancer
MDA-MB-231 cells.Control cells (EV) and MDA-MB-231 stably expressing shRNA against
COMMD1 (KD) were plated in 96-well plates and treated with indicated concentrations of cis-
platin. After 72 hours of treatment, cells were incubated with MTT for 3 hours and the viability
of cells was determined by colorimetricmeasurement. Data are shown from three independent
experiments. Statistical significancewas calculated using the Student's t-test. : P< 0.05.
(PDF)
S3 Fig. Full scans of the western blots.
(TIF)
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